MiMedx Group (NASDAQ:MDXG) Hits New 52-Week Low – What’s Next?

MiMedx Group, Inc (NASDAQ:MDXG)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $3.77 and last traded at $3.86, with a volume of 924041 shares trading hands. The stock had previously closed at $3.81.

Analyst Ratings Changes

MDXG has been the topic of a number of research analyst reports. Citigroup initiated coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating on the stock. Mizuho decreased their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. UBS Group set a $10.00 target price on shares of MiMedx Group in a research report on Monday, February 23rd. Finally, Cantor Fitzgerald cut their price target on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Stock Up 1.3%

The business has a fifty day moving average price of $4.83 and a two-hundred day moving average price of $6.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. The firm has a market capitalization of $573.48 million, a price-to-earnings ratio of 12.06 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%. On average, equities analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Institutional Trading of MiMedx Group

Several large investors have recently made changes to their positions in MDXG. PNC Financial Services Group Inc. increased its stake in shares of MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after acquiring an additional 7,107 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of MiMedx Group during the fourth quarter worth $48,000. State of Alaska Department of Revenue acquired a new position in MiMedx Group during the third quarter valued at $54,000. Headlands Technologies LLC purchased a new stake in MiMedx Group in the second quarter valued at $72,000. Finally, Jain Global LLC purchased a new stake in MiMedx Group in the fourth quarter valued at $73,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.